Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Nanobiotix S.A.NASDAQ: NBTX

Deferred Revenue · Q4 FY2025 · quarter ended Dec 2025

Deferred revenue rises 99.4% from a year ago

Deferred revenue stood at €36.22M at the end of Q4 FY2025, up 99.4% from a year earlier. Over 3 fiscal years it compounded at +29.8% a year.

Context

  • Deferred revenue amounted to 53.4% of total assets at the end of Q4 FY2025, up 26.5 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps rising in the next quarterly balance sheet after a +99.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
€36.22M— QoQ
Last fiscal yearDec 2025
€36.22M+99.4% YoY
Year agoDec 2024
€18.16M+99.4% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+99.4%——
1 year+99.4%——
3-year CAGR+29.8%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

EUR · from the balance sheet

Latest · FY2025
36.22M EUR
Year-over-year change
+99.4%
4-year CAGR
+21.2%

Deferred Revenue vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +99.4% is the highest of 2, against a peer median of +16.8%.
  • Deferred revenue amounts to 53.4% of total assets for NBTX, versus a peer median of 0.0%.
NBTX Competitors
Deferred Revenue for NBTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KURAKura Oncology, Inc.Mar 2026$47.7M USD+16.8%—7.3%
NBTXNanobiotix S.A.Dec 2025€36.22M EUR+99.4%+29.8%53.4%
CADLCandel Therapeutics, Inc.Mar 2026$67K USD——0.0%
IBRXImmunityBio, Inc.Sep 2026$0 USD——0.0%
TYRATyra Biosciences, Inc.Mar 2026$0 USD——0.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$0 USD——0.0%
NVCTNuvectis Pharma, Inc.Mar 2026$0 USD——0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$0 USD——0.0%
IMMXImmix Biopharma, Inc.Mar 2026$0 USD——0.0%
PBYIPuma Biotechnology, Inc.Mar 2026$0 USD——0.0%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding NBTX) —+16.8%—0.0%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents83.92M41.39M75.28M49.74M52.75M
Short-term Investments00000
Net Receivables3.89M2.84M2.97M8.54M7.68M
Inventory02.98M200K00
Other Current Assets3.04M2.17M6.33M(1K)2K
Total Current Assets93.06M52.36M87.34M61.47M62.75M
Property, Plant & Equipment (Net)8.19M7.12M6.11M5.54M4.57M
Goodwill00000
Intangible Assets4K1K8K7K10K
Long-term Investments98K0000
Tax Assets00000
Other Non-current Assets421K291K443K406K434K
Total Non-current Assets8.71M7.41M6.56M5.95M5.01M
Total Assets101.77M59.77M93.9M67.42M67.76M
Account Payables5M4M6.7M4.48M6.58M
Short-term Debt7.08M3.6M3.82M3.66M3.1M
Tax Payables5.08M6.6M7.38M6.87M6.82M
Deferred Revenue16.77M16.57M18.23M18.16M36.22M
Other Current Liabilities5.39M7.41M760K8.27M430K
Total Current Liabilities36.85M37.94M49.87M58.94M57.51M
Long-term Debt32.42M44.04M41.66M43.01M89.12M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities318K270K325K28.21M3.73M
Total Non-current Liabilities38.13M48.88M45.87M74.19M94.74M
Total Liabilities74.98M86.81M95.74M133.12M152.24M
Common Stock1.05M1.05M1.41M1.42M1.45M
Retained Earnings(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Accumulated OCI(182.82M)(226.58M)(276.07M)(311.51M)(376.15M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity26.79M(27.05M)(1.84M)(65.7M)(84.48M)
Total Debt46.02M53.17M50.57M50.9M95.32M
Net Debt(37.9M)11.78M(24.72M)1.17M42.57M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.